The results, published in Journal of Heart and Lung Transplantation, implanted the Jarvik 2015 Ventricular Assist Device in seven children ages 8 months to 7 years. The children spent months using the device before their transplant and were able to participate in normal play activities. All the children survived, though one child — whose heart recovered and thus did not require a transplant — had a stroke on the 53rd day following device implantation.
The device is not FDA approved.
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
